JASPER THERAPEUTICS, INC. (JSPR) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | 44.03M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $44.03M | (m) |
| 2026-03-31 | (m) | $-55.73M | (m) |
| 2025-12-31 | (m) | $-75.80M | (m) |
| 2025-09-30 | (m) | $-91.02M | (m) |
| 2025-06-30 | (m) | $-90.92M | (m) |
| 2025-03-31 | (m) | $-78.78M | (m) |
| 2024-12-31 | (m) | $-71.27M | (m) |
| 2024-09-30 | (m) | $-63.53M | (m) |
| 2024-06-30 | (m) | $-62.44M | (m) |
| 2024-03-31 | (m) | $-63.93M | (m) |
| 2023-12-31 | (m) | $-64.47M | (m) |
| 2023-09-30 | (m) | $-61.09M | (m) |
| 2023-06-30 | (m) | $-55.41M | (m) |
| 2023-03-31 | (m) | $-49.74M | (m) |
| 2022-12-31 | (m) | $-37.69M | (m) |
| 2022-09-30 | (m) | $-33.53M | (m) |
| 2022-06-30 | (m) | $-25.08M | (m) |
| 2022-03-31 | (m) | $-23.09M | (m) |
| 2021-12-31 | (m) | $-30.64M | (m) |
| 2021-09-30 | (m) | $-6.58M | (m) |
| 2021-06-30 | (m) | $-2.55M | (m) |
| 2021-03-31 | (m) | $-2.41M | (m) |
| 2020-12-31 | (m) | $-590.70K | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) |
| 2019-08-30 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |